PDF(Pubmed)
Abstract：
BACKGROUND: Embryo transfer (ET) is an important step in assisted reproductive technology. Uterine length measurement before ET (ULMbET) enables the determination of catheter length and anatomical variation before the ET. Therefore, in this study, we aim to compare ULMbET and transabdominal ultrasound-guided ET (TAUGET).
METHODS: This open-label randomised clinical trial enrolled 264 women who were scheduled for frozen- thawed ET (FET) cycles. The women were randomised to the ULMbET or TAUGET group for ET. The primary outcome of this study was clinical pregnancy.
RESULTS: A total of 132 women were randomly assigned to the ULMbET group and 132 women to the TAUGET group. However, four women in the ULMbET group did not receive the allocated method after randomisation. Finally, 128 women from the ULMbET group and 132 women from the TAUGET group were assessed. No statistically significant differences existed in chemical pregnancy rate (31.3 vs. 36.4%, P=0.384), clinical pregnancy rate (23.4 vs. 28%, P=0.397), and implantation rate (15 vs. 17.8%, P=0.401) between the ULMbET and TAUGET groups, respectively.
CONCLUSIONS: The results of this clinical trial show no differences in pregnancy outcomes in FET cycles following ULMbET and TAUGET (registration number: IRCT20110509006420N240).
METHODS: This open-label randomised clinical trial enrolled 264 women who were scheduled for frozen- thawed ET (FET) cycles. The women were randomised to the ULMbET or TAUGET group for ET. The primary outcome of this study was clinical pregnancy.
RESULTS: A total of 132 women were randomly assigned to the ULMbET group and 132 women to the TAUGET group. However, four women in the ULMbET group did not receive the allocated method after randomisation. Finally, 128 women from the ULMbET group and 132 women from the TAUGET group were assessed. No statistically significant differences existed in chemical pregnancy rate (31.3 vs. 36.4%, P=0.384), clinical pregnancy rate (23.4 vs. 28%, P=0.397), and implantation rate (15 vs. 17.8%, P=0.401) between the ULMbET and TAUGET groups, respectively.
CONCLUSIONS: The results of this clinical trial show no differences in pregnancy outcomes in FET cycles following ULMbET and TAUGET (registration number: IRCT20110509006420N240).
摘要：
背景：胚胎移植（ET）是辅助生殖技术的重要步骤。ET之前的子宫长度测量（ULMbET）可以确定ET之前的导管长度和解剖变化。因此,在这项研究中，我们的目的是比较ULMbET和经腹超声引导的ET（TAUGET）。
方法：这项开放标签的随机临床试验纳入了264名计划进行冻融ET（FET）周期的女性。这些妇女被随机分配到ULMbET或TAUGET组进行ET。这项研究的主要结果是临床妊娠。
结果：共有132名女性被随机分配到ULMbET组，132名女性被随机分配到TAUGET组。然而,ULMbET组的4名女性在随机分组后未接受分配方法.最后,对来自ULMbET组的128名妇女和来自TAUGET组的132名妇女进行了评估。化学妊娠率无统计学差异(31.3vs.36.4%,P=0.384),临床妊娠率（23.4vs.28%,P=0.397),和植入率(15vs.17.8%,ULMbET和Tauget组之间的P=0.401），分别。
结论：本临床试验结果显示ULMbET和TAUGET后FET周期的妊娠结局无差异（注册号：IRCT20110509006420N240）。
方法：这项开放标签的随机临床试验纳入了264名计划进行冻融ET（FET）周期的女性。这些妇女被随机分配到ULMbET或TAUGET组进行ET。这项研究的主要结果是临床妊娠。
结果：共有132名女性被随机分配到ULMbET组，132名女性被随机分配到TAUGET组。然而,ULMbET组的4名女性在随机分组后未接受分配方法.最后,对来自ULMbET组的128名妇女和来自TAUGET组的132名妇女进行了评估。化学妊娠率无统计学差异(31.3vs.36.4%,P=0.384),临床妊娠率（23.4vs.28%,P=0.397),和植入率(15vs.17.8%,ULMbET和Tauget组之间的P=0.401），分别。
结论：本临床试验结果显示ULMbET和TAUGET后FET周期的妊娠结局无差异（注册号：IRCT20110509006420N240）。
